{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=BRAF-mutated+Tumors", "query": { "condition": "BRAF-mutated Tumors" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 136, "total_pages": 14, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=BRAF-mutated+Tumors&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-07-24T01:00:21.310Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT05217446", "title": "A Study of Encorafenib Plus Cetuximab Taken Together With Pembrolizumab Compared to Pembrolizumab Alone in People With Previously Untreated Metastatic Colorectal Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Colorectal Cancer" ], "interventions": [ { "name": "Encorafenib", "type": "DRUG" }, { "name": "Cetuximab", "type": "BIOLOGICAL" }, { "name": "Pembrolizumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "16 Years", "maximum_age": null, "sex": "ALL", "summary": "16 Years and older" }, "enrollment_count": 107, "start_date": "2022-07-11", "completion_date": "2027-01-26", "has_results": false, "last_update_posted_date": "2026-04-07", "last_synced_at": "2026-07-24T01:00:21.310Z", "location_count": 6, "location_summary": "Phoenix, Arizona • Scottsdale, Arizona • Miami Beach, Florida + 2 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Miami Beach", "state": "Florida" }, { "city": "Germantown", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT05217446" }, { "nct_id": "NCT02027961", "title": "Phase 1 Safety and Tolerability of MEDI4736 in Combination With Dabrafenib and Trametinib or With Trametinib Alone", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Melanoma" ], "interventions": [ { "name": "Durvalumab", "type": "BIOLOGICAL" }, { "name": "Dabrafenib", "type": "DRUG" }, { "name": "Trametinib", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "MedImmune LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 68, "start_date": "2013-12-20", "completion_date": "2018-04-24", "has_results": false, "last_update_posted_date": "2019-05-17", "last_synced_at": "2026-07-24T01:00:21.310Z", "location_count": 7, "location_summary": "Scottsdale, Arizona • Los Angeles, California • San Francisco, California + 4 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Miami Beach", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT02027961" }, { "nct_id": "NCT01264380", "title": "A Study of the Effect of Food on the Pharmacokinetics of Single Dose RO5185426 And the Safety And Efficacy of Continuous Administration in Patients With BRAF V600E Mutation-Positive Metastatic Melanoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Malignant Melanoma" ], "interventions": [ { "name": "RO5185426", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 16, "start_date": "2011-01", "completion_date": "2013-05", "has_results": true, "last_update_posted_date": "2016-11-02", "last_synced_at": "2026-07-24T01:00:21.310Z", "location_count": 10, "location_summary": "La Jolla, California • Los Angeles, California • San Francisco, California + 7 more", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Indianapolis", "state": "Indiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT01264380" }, { "nct_id": "NCT05388877", "title": "E6201 and Dabrafenib for the Treatment of Central Nervous System Metastases From BRAF V600 Mutated Metastatic Melanoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Clinical Stage IV Cutaneous Melanoma AJCC v8", "Metastatic Malignant Neoplasm in the Brain", "Metastatic Malignant Neoplasm in the Central Nervous System", "Metastatic Melanoma" ], "interventions": [ { "name": "Dabrafenib", "type": "DRUG" }, { "name": "MEK-1/MEKK-1 Inhibitor E6201", "type": "DRUG" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "Mayo Clinic", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 13, "start_date": "2022-10-20", "completion_date": "2025-06-02", "has_results": false, "last_update_posted_date": "2025-08-19", "last_synced_at": "2026-07-24T01:00:21.310Z", "location_count": 3, "location_summary": "Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT05388877" }, { "nct_id": "NCT01351103", "title": "A Study of LGK974 in Patients With Malignancies Dependent on Wnt Ligands", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Pancreatic Cancer", "BRAF Mutant Colorectal Cancer", "Melanoma", "Triple Negative Breast Cancer", "Head and Neck Squamous Cell Cancer", "Cervical Squamous Cell Cancer", "Esophageal Squamous Cell Cancer", "Lung Squamous Cell Cancer" ], "interventions": [ { "name": "LGK974", "type": "DRUG" }, { "name": "PDR001", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 185, "start_date": "2011-12-01", "completion_date": "2024-06-17", "has_results": false, "last_update_posted_date": "2025-06-13", "last_synced_at": "2026-07-24T01:00:21.310Z", "location_count": 6, "location_summary": "Los Angeles, California • Baltimore, Maryland • Boston, Massachusetts + 3 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Ann Arbor", "state": "Michigan" }, { "city": "Detroit", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT01351103" }, { "nct_id": "NCT01877811", "title": "Study of RXDX-105, Potent RET Inhibitor in Patients With Advanced Lung Cancer and Other Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Solid Tumors" ], "interventions": [ { "name": "RXDX-105", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 143, "start_date": "2013-06", "completion_date": "2019-02", "has_results": false, "last_update_posted_date": "2019-04-25", "last_synced_at": "2026-07-24T01:00:21.310Z", "location_count": 14, "location_summary": "Duarte, California • Irvine, California • San Diego, California + 10 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Irvine", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Sarasota", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT01877811" }, { "nct_id": "NCT03975231", "title": "Dabrafenib, Trametinib, and IMRT in Treating Patients With BRAF Mutated Anaplastic Thyroid Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "BRAF NP_004324.2:p.V600E", "BRAF V600K Mutation Present", "Thyroid Gland Anaplastic Carcinoma" ], "interventions": [ { "name": "Dabrafenib", "type": "DRUG" }, { "name": "Intensity-Modulated Radiation Therapy", "type": "RADIATION" }, { "name": "Trametinib", "type": "DRUG" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "City of Hope Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 6, "start_date": "2020-09-14", "completion_date": "2027-10-05", "has_results": false, "last_update_posted_date": "2026-04-08", "last_synced_at": "2026-07-24T01:00:21.310Z", "location_count": 3, "location_summary": "Duarte, California • Columbus, Ohio • Houston, Texas", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Columbus", "state": "Ohio" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03975231" }, { "nct_id": "NCT07224841", "title": "Development of a cfDNA 5mC/5hmC-based Biomarker Panel to Predict Targeted Therapy Efficacy in mCRC", "overall_status": "RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "CRC (Colorectal Cancer)" ], "interventions": [ { "name": "cfDNA 5mC/5hmC Sequencing (EpiDRIVE Discovery Phase)", "type": "DIAGNOSTIC_TEST" }, { "name": "EpiDRIVE Assay (Targeted Sequencing / qPCR Validation)", "type": "DIAGNOSTIC_TEST" } ], "intervention_types": [ "DIAGNOSTIC_TEST" ], "sponsor": "City of Hope Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 500, "start_date": "2024-06-21", "completion_date": "2028-06-18", "has_results": false, "last_update_posted_date": "2026-07-07", "last_synced_at": "2026-07-24T01:00:21.310Z", "location_count": 1, "location_summary": "Duarte, California", "locations": [ { "city": "Duarte", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT07224841" }, { "nct_id": "NCT01954043", "title": "A Pharmacokinetics (PK) Study of the Effects Rabeprazole and Rifampin on Dabrafenib in Subjects With BRAF V600 Mutation Positive Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Cancer" ], "interventions": [ { "name": "Dabrafenib 150 mg twice a day (BID)", "type": "DRUG" }, { "name": "Rabeprazole 40 mg once daily (OD)", "type": "DRUG" }, { "name": "Rifampin 600 mg OD", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 23, "start_date": "2013-12-20", "completion_date": "2016-02-29", "has_results": false, "last_update_posted_date": "2017-11-14", "last_synced_at": "2026-07-24T01:00:21.310Z", "location_count": 3, "location_summary": "Goodyear, Arizona • Dallas, Texas • Tacoma, Washington", "locations": [ { "city": "Goodyear", "state": "Arizona" }, { "city": "Dallas", "state": "Texas" }, { "city": "Tacoma", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT01954043" }, { "nct_id": "NCT04675710", "title": "Pembrolizumab, Dabrafenib, and Trametinib Before Surgery for the Treatment of BRAF-Mutated Anaplastic Thyroid Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Thyroid Gland Anaplastic Carcinoma", "Thyroid Gland Squamous Cell Carcinoma" ], "interventions": [ { "name": "Conventional Surgery", "type": "PROCEDURE" }, { "name": "Dabrafenib", "type": "DRUG" }, { "name": "Intensity-Modulated Radiation Therapy", "type": "RADIATION" }, { "name": "Pembrolizumab", "type": "BIOLOGICAL" }, { "name": "Quality-of-Life Assessment", "type": "OTHER" }, { "name": "Trametinib", "type": "DRUG" } ], "intervention_types": [ "PROCEDURE", "DRUG", "RADIATION", "BIOLOGICAL", "OTHER" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 30, "start_date": "2021-06-24", "completion_date": "2026-10-30", "has_results": false, "last_update_posted_date": "2026-02-19", "last_synced_at": "2026-07-24T01:00:21.310Z", "location_count": 6, "location_summary": "Stanford, California • Ann Arbor, Michigan • Rochester, Minnesota + 3 more", "locations": [ { "city": "Stanford", "state": "California" }, { "city": "Ann Arbor", "state": "Michigan" }, { "city": "Rochester", "state": "Minnesota" }, { "city": "Cleveland", "state": "Ohio" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04675710" } ] }